EV Biologics (EV Biologics) Gross-Profit-to-Asset % : 146.60% (As of Dec. 2017)

View and export this data going back to 2015. Start your Free Trial

What is EV Biologics Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. EV Biologics's annualized Gross Profit for the quarter that ended in Dec. 2017 was $67.61 Mil. EV Biologics's average Total Assets over the quarter that ended in Dec. 2017 was $46.12 Mil. Therefore, EV Biologics's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2017 was 146.60%.

EV Biologics Gross-Profit-to-Asset % Historical Data

The historical data trend for EV Biologics's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

EV Biologics Gross-Profit-to-Asset % Chart

EV Biologics Annual Data

Trend

Jun13

Jun14

Jun15

Jun16

Jun17

Gross-Profit-to-Asset %

27.50

26.77

22.92

28.90

5.44

EV Biologics Quarterly Data
	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Jun17	Dec17
Gross-Profit-to-Asset %	Get a 7-Day Free Trial												11.68	10.05	188.23	-	146.60

Competitive Comparison of EV Biologics's Gross-Profit-to-Asset %

For the Biotechnology subindustry, EV Biologics's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

EV Biologics's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, EV Biologics's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where EV Biologics's Gross-Profit-to-Asset % falls into.

EV Biologics Gross-Profit-to-Asset % Calculation

EV Biologics's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Jun. 2017 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Jun. 2017 )	/	( (Total Assets (A: Jun. 2016 )	+	Total Assets (A: Jun. 2017 ))	/ count )
	=	1.896	/	( (36.443	+	33.278)	/ 2 )
	=	1.896	/	34.8605
	=	5.44 %

EV Biologics's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2017 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Dec. 2017 )	/	( (Total Assets (Q: Jun. 2017 )	+	Total Assets (Q: Dec. 2017 ))	/ count )
	=	67.608	/	( (33.278	+	58.954)	/ 2 )
	=	67.608	/	46.116
	=	146.60 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Dec. 2017) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

EV Biologics Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of EV Biologics's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

EV Biologics (EV Biologics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » EV Biologics Inc (OTCPK:YECO) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

XCNQ:NIRV ENVB BLCM NLSP BRTX ADTX XKRX:066830 ALLR XMAD:ADL ARTL

Traded in Other Exchanges

N/A

Address

1621 Central Avenue, Cheyenne, WY, USA, 82001

Website

https://www.evbiologics.com

EV Biologics Inc is developing the extraordinary biological properties of extracellular vesicles (EVs) to create the next generation of diagnostic modalities and safe, effective biotherapeutics to improve outcomes of serious clinical conditions, increase natural longevity and transform lives.

Executives

Daniel S Mckinney	director, 10 percent owner, officer: CEO	TWO IFC, 19TH FLOOR, 8 FINANCE STREET, CENTRAL, HONG KONG F4 000000
Michael W Harlan	director	C/O WASTE CONNECTIONS, INC., 610 APPLEWOOD CRESCENT, SUITE 200, VAUGHAN A6 L4K 0C3